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Abstract
Background: The level of funding provides a good proxy for the level of commitment or prioritisation given to a
particular issue. While the need for research relevant to social, economic, cultural and behavioural aspects of
neglected tropical diseases (NTD) control has been acknowledged, there is limited data on the level of funding
that supports NTD social science research.
Method: A case study was carried out in which the spending of a major independent funder, the Bill and Melinda
Gates Foundation (BMGF) - was analysed. A total of 67 projects funded between October 1998 and November
2008 were identified from the BMGF database. With the help of keywords within the titles of 67 grantees, they
were categorised as social science or non-social science research based on available definition of social science. A
descriptive analysis was conducted.
Results: Of 67 projects analysed, 26 projects (39%) were social science related while 41 projects (61%) were basic
science or other translational research including drug development. A total of US$ 697 million was spent to fund
the projects, of which 35% ((US$ 241 million) went to social science research. Although the level of funding for
social science research has generally been lower than that for non-social science research over 10 year period,
social science research attracted more funding in 2004 and 2008.
Conclusion: The evidence presented in this case study indicates that funding on NTD social science research
compared to basic and translational research is not as low as it is perceived to be. However, as there is the acute
need for improved delivery and utilisation of current NTD drugs/technologies, informed by research from social
science approaches, funding priorities need to reflect the need to invest significantly more in NTD social science
research.
Introduction
The neglected tropical diseases (NTDs) are a group of
13 parasitic and bacterial infections (e.g. ascariasis, lym-
phatic filariasis, leprosy and trachoma). They are major
disabling conditions affecting mostly the world’s poorest
people [1]. NTDs are preventable infectious diseases
that had been neglected by major stakeholders including
media, governments and organisations working in the
health sector. This neglect, coupled with poverty and
inadequate treatment and control programmes, aggra-
vated the impact of these diseases in very deprived com-
munities [2]. Not surprisingly, the research in NTDs
had also been neglected. A critical reason for this has
been the lack of funding to advance research and devel-
opment for neglected disease control. A recent publica-
tion estimates that although just over US$2.5 billion was
invested into research and development (R&D) for dis-
eases of poverty, 80% of this funding went into the big
three HIV/AIDS, TB and Malaria [3]. Furthermore,
most of this funding went into the development of
drugs and vaccines. To address the lack of focus on
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research for NTDs a number of advocates and stake-
holders have partnered with national ministries of health
and pharmaceutical industries towards the control or
elimination the most prevalent NTDs [1]. Similar initia-
tives have led to a sudden surge in non-commercial R&D
in NTDS post 2000 [4] and there are currently about 92
public-private partnerships devoted in this area [5].
The neglected areas of research are interfaces between
basic science research, product development research,
implementation research, other policy and social science
research and, last but not the least, the actual large scale
disease control programmes themselves [6]. While
research on each of these interfaces is critical, the global
research effort on NTDs has been diverse and fragmented
with a great imbalance in the areas of coverage [3,7,8].
The scale of social science research in the neglected
tropical diseases (NTDs) is particularly fragmented and
less prominent compared to other areas of research (see
[9,10] in this series). Some argue that there is already a
significant extant body of research in the social sciences
on NTDs; however there is also a perception that these
studies are not on a par with research on other diseases
[11,12]. That there is a role for social science research
generally is not in doubt - recent discussions on the
breakthroughs in R&D for neglected diseases suggest
that there are, for instance, opportunities for better-tar-
geted policies extending beyond drug discovery [4].
Areas highlighted include social research on community
diagnosis, community participation in the frontline and
implementation research [13]. Although these constitute
an attempt to articulate a research agenda, there is still
no coherent theme or research priority area identified
from the social sciences that could lead to a cumulative
body of evidence relevant to NTD control. A common
reason given for this is the relatively limited funding
specifically for social science research in NTDs. Global
health trends and the advocacy for NTDs clearly
demonstrate that the availability of funding is a powerful
driver of research agenda.
Moran et al. provide the most comprehensive data
related to neglected disease research and development
[3]. According to them, just over US$ 2.5 billion was
invested into R&D of new neglected disease products in
2007, a majority (80%) of which, as previously men-
tioned, went to the three big diseases- HIV/AIDS, TB
and malaria. This funding was heavily focussed on drugs
and vaccines. Platform technologies that included vac-
cine adjuvants, diagnostic and delivery technologies
received less than 0.4% of the total R&D spending. The
major donors were public and philanthropic institutions
that invested 69% and 21% of the total spending respec-
tively. About 9% of the funding came from the private
pharmaceutical sector. These data provide information
about the scale and the nature of NTD research and
development. They highlight for instance that research
in this area is funded primarily by the BMGF and
National Institutes of Health (NIH) in the US. Most of
the NIH research dollars are spent on basic science and
translational research to bring new drugs and technolo-
gies to the market [14]. For conditions prevalent in
developing countries such as that related to child mor-
tality, 97% of NIH and Gates monies were in fact spent
on creating new technologies [15].
In this paper, we attempt to aid the debate whether
both the level and spread of social science research
funding is adequate relative to creating new technologies
by analysing the expenditure of a leading funder in the
area of NTD research and development. This is a part
of a larger study looking at the current status of social
science research in neglected tropical diseases (see
[9,10,16] in this series). While a wider survey including
all funders could have been an ideal approach, tracking
funding sources specifically for social science research is
complex and information provided through the publica-
tions is inconsistent [17]. Many authors do not identify
their sources of funding in the published articles. Even
in instances where funding for the research is acknowl-
edged, stating the amount received is not a usual prac-
tice. Therefore, we chose an alternative approach of
assessing funding flows in to the social science research
in NTDs focusing on one lead funding organisation- the
Bill and Melinda Gates Foundation or BMGF (Addi-
tional file 1: Box 1). It is the second largest funder of
NTD research and development as found by Moran et
al. [3] and the data on BMGF funding grantees is openly
available. The most obvious limitation with this
approach however is that it was sometimes difficult to
distinguish between funding allocated specifically to
social science research and funds allocated for the
implementation of programmes and for the evaluation
of those programmes. In addition, even though we
focused on BMGF and examined its funding mechan-
ism, we acknowledge that this does not give a compre-
hensive picture. It does however provide a significant
proportion of funding for social science research on
NTDs globally. We excluded other funders because it
was not feasible to track their funding in the way that
allowed us to make any distinction between social
science and non-social science research in the NTDs.
Methods
We searched the BMGF database online. In order to
find the relevant social science studies, we first went to
the “Search Past Grants” site available at http://www.
gatesfoundation.org/grants/Pages/search.aspx which lists
all grants that the Foundation has made in the past
years. We then filtered the search by checking respec-
tively the “neglected diseases”, “2007 and earlier” and
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“2008” boxes found on the left hand side menu. The
search was carried out in November 2009. A total of 68
titles were identified. These included grants between
October 1998 and November 2008. The identified grant
titles had information about the purpose of the projects,
date when it was awarded, amount and term of the
grant, the region the grant served, the BMGF pro-
gramme under which it was allocated (all Global Health)
and the location of the Grantee.
Based on this data, we identified keywords within the
very limited information contained in the titles and pur-
pose fields of identified grantees and then categorised
them as social science research or non-social science
research. The basis of the categorisation was the defini-
tion of social science provided in a recent report [18]
which states,
“[T]he relevance of these [social science] disciplines
to public health and disease control is in ... the
applied areas of anthropology, demography, econom-
ics, human geography, psychology, politics, history,
law, social policy, and sociology”. [18]
As it was not always possible to identify in the titles
the specific discipline under which the identified grant
operated, we further utilised a more specific definition
given in the same report-
“Applied social science for public health is ...defined
as an interdisciplinary and dynamic field which inte-
grates the knowledge and tools for research and ana-
lysis from a range of social science disciplines for the
purposes of understanding the various determinants
of health in individuals and populations and devel-
oping, implementing and evaluating sustainable solu-
tions to public health problems”.[18]
To illustrate the process of categorisation, consider
two examples. Two of the identified titles had the fol-
lowing information on their purpose fields: “to deter-
mine the impact of integrated trachoma and lymphatic
filariasis control programs on infection prevalence.” and
“to develop highly effective, inexpensive new drugs to
treat late stages of trypanosomiasis and leishmaniasis”.
Based on the definition of social science research as
described above, the former was identified as a social
science research as the project was more likely to sit in
one or more of the disciplines identified in the defini-
tion. The latter was a non-social science research as it
was a drug development project.
Other variables of interests included some basic infor-
mation about the grantees (institutional type, location,
amount received, term of award, and year) as well as the
beneficiary’s region. To compare the funds received for
various purposes on relative basis, we generated another
indicator- the total grant received per calendar year. A
descriptive analysis was carried out by stratifying the
total number of projects into two: (a) social science
research; and (b) non-social science research.
Results
For the period 1998 to 2008, a total of 68 projects
related to NTD’s were funded by the BMGF. After
screening the purpose of the funding, 67 projects were
identified and the available data on those projects were
analysed. One project - a scholarship program aimed at
encouraging students to pursue university degrees that
are not necessarily NTD-based - was excluded because
it was difficult to decipher its direct link to NTD’s.
Additional file 2 and 3 (Appendices 1 and 2) list the
projects selected for this analysis.
The 67 projects were from 5 different continents.
Majority (55%) of projects were from Africa followed by
Asia (28%) with the remaining covering Europe, as well
as North and South America. However, the grantees
were mainly located in the US (76%), Switzerland (13%)
and the UK (10%). As shown in Figure 1 most (61%) of
the projects involved research related to non-social
science with the main focus on drug development.
About 64% (n = 43) of the projects were associated with
academic research institutions while the rest were
related to non-government organisations (33%) and
other institutions (3%).
During the review period, a total of US$ 697 million
was allocated to fund the projects, with amounts ranging
from US$ 33,150 to US$ 55 million dispensed for pro-
jects that lasted from 4 months to about 10 years. Of
these US$ 456 million were allocated to research related
to non-social science and US$ 241 million to social
science research (Figure 2). In terms of average funds
allocated per year, social science research received
US$ 1.97 million compared with US$ 2.35 million that
Figure 1 Location of Grantees.
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went to non-social science research. Although the level
of funding for social science research has generally been
lower than that for non-social science research over
10 year period, social science research attracted more
funding in 2004 (US$ 14.97 million) and 2008 (US$ 45.84
million) compared to non social science research (US$
0.57 and 8.72 million respectively in 2004 and 2008).
In order to review the range of recipients of the funds,
the grantees were divided into three broad groups- (a)
academic and research institutions (ARI) that included
Universities and research centres; (b) non-governmental
organisations (NGO) that included not-for-profit institu-
tions; and (c) others that included institutions that were
not ARIs or NGOs. As shown in Figure 3 most of the
funding for social science research was allocated to non-
governmental organisations while academic research
institutes were the biggest beneficiaries in terms of
receiving funds for non-social science research.
Discussion
This paper presented a case study of social science fund-
ing based on one lead funding organisation- the Bill and
Melinda Gates Foundation. The reliance on one funder
to provide an indication of the proportion of total
research spending going to social science research may
not have given us the true picture of the scale of fund-
ing in the NTD social science research. However, it
does constitute a systematic attempt to explore the
commonly held assumption that funding allocated to
social science research is limited. Including all other
funders in the analysis could have improved the preci-
sion of the scale of funding but it might not have altered
the observed proportion of such funding and more
importantly the conclusion that there exists a noticeable
difference between social and non-social science
research dollars spent on NTDs. Another limitation was
that some of the projects which we considered as social
science research may also have programmatic or imple-
mentation components. Due to limited information
available, it was not possible to separate research costs
from programme costs. It does however demonstrate
that investment in social science research is less than
whatever estimates could be gleaned from this case
study.
An important finding from this case study is that cen-
tral to increased discussions on the need for NTD con-
trol is the primacy given to basic and translational
research into new drugs and technological development.
This notwithstanding the evidence that improving the
“fidelity” of health care delivery and utilisation (predo-
minantly a social science approach) actually raises the
population health status significantly more than the
research to develop a more efficacious new drug or
technology [14,15]. Given the compelling data on the
existing cost effective drugs and technologies to treat
NTDs at a unit cost of about US$0.50, so little effort
appears to be going into the sorts of questions that will
enhance the delivery of these technologies to the target
populations. Thus, there is a need for intensified advo-
cacy for more funding to be made available for social
science evidence to support this effort. However, this
need not imply that cuts in basic/translational research
are necessary to do this as it is not clear whether the
scale of funding disparities observed in this case study
between social-science and basic/translational research
is appropriate enough to warrant that.
The pattern of funding from the BMGF provides some
interesting implications. Although almost all debates
around funding research in NTDs revolve around drug/
technology development, the notion that social science
research in the NTDs receives significantly less funding
relative to research in to basic science and drug devel-
opment may be exaggerated, particularly over the last
five to ten years. In the case of BMGF, this may have
been due to the fact that the BMGF aims to support
sustainable ways to improve delivery where proven tools
Figure 2 NTD Social science research funded by Bill & Melinda
Gates Foundation 1998-2008.
Figure 3 Bill & Melinda Gates Foundation disbursements by
type of grantees (1998-2008). Red: Non-governmental
Organisation. Blue: Academic and Research Institutes. Green: Others.
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exist [2]. This goal is also reflected in the partnerships
and NGOs to realise the benefits of existing tools. How-
ever, the gap in social versus non-social science research
funding is still significant (35/65). Given the acute need
for improved delivery and utilisation of current drugs/
technologies, informed by research from social science
approaches, funding priorities need to reflect the need
to invest significantly more in social science. At the very
least there is an urgent need for an assessment and
debate around the opportunity costs of investing any
future dollars in developing a new NTD drug or
technology.
We observed a couple of interesting disparities in
funding social science research in the case of BMGF.
First, academic/research environment received less fund-
ing compared to NGOs. This could be explained by the
fact that most of such research actually required the
delivery/implementation of current tools (drugs/therapy/
technology). NGOs and partnerships, many of whom are
involved in direct service delivery, are better placed to
undertake these activities. However, this observation
should be located in an important caveat of our method
of this case study- our inability to make a clear distinc-
tion in some cases between funding allocated specifically
to social science research and funds allocated for the
implementation of programmes and for the evaluation
of those programmes. Some NGOs might have just been
implementing current tools as opposed to doing
research. Nevertheless, future funding decisions may
consider whether a partnership between social science
researchers from the academia/research institutions and
the NGOs may provide a better model (see [10,16] in
this series). Secondly, funds for projects in lower and
middle income countries are mainly awarded to institu-
tions based in high-income countries. This raises yet
another important but traditionally identified issue- the
lack of research capacity in low-income countries, the
home of NTDs. We were unable to explore this issue
further in this case study.
Finally, the level of funding provides a good proxy for
the level of commitment or prioritisation given to a par-
ticular issue [19]. It is therefore difficult to argue that
the social, economic, cultural and behavioural aspects of
NTD control are considered important to address when
the funding is not made available to support it. The
other analyses presented in this series of papers [9,10]
show that the nature of projects that are funded focus
on support for existing interventions through evaluation,
understanding community drivers, health systems bottle-
necks, and in broad programmatic areas although there
is still extensive, systematic work that needs to be
undertaken in these areas. Furthermore, these analyses
also show that the full potential of the possible contri-
bution that the wide range of social science disciplines
could make to neglected populations has been barely
tapped [9]. This means that a clear social science agenda
and some good advocacy for social science research on
NTDs are needed to attract more research funding to
this area.
Conclusion
The evidence presented in this case study indicates that
the notion that social science research in the NTDs
receives significantly less funding relative to research in
to basic science and drug development may be exagger-
ated, particularly over the last five to ten years. How-
ever, as there is the acute need for improved delivery
and utilisation of current drugs/technologies, informed
by research from social science approaches, funding
priorities need to reflect the need to invest significantly
more in social science research. Future research could
look at how best this goal can be achieved- through cuts
in any future dollars in developing a new NTD drug/
technology or increased investment in social science stu-
dies independent of basic/translational research.
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